Patents by Inventor Charlotte Schou Hunneche

Charlotte Schou Hunneche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for thioether conjugation of proteins
    Patent number: 11219690
    Abstract: The invention relates to methods for obtaining a protein conjugate wherein a cysteine residue of the protein serves as attachment point for the chemical moiety conjugated to the protein.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: January 11, 2022
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Charlotte Schou Hunneche, Thomas Budde Hansen, Ernst Broberg Hansen
  • Method for Thioether Conjugation of Proteins
    Publication number: 20160303248
    Abstract: The invention relates to methods for obtaining a protein conjugate wherein a cysteine residue of the protein serves as attachment point for the chemical moiety conjugated to the protein.
    Type: Application
    Filed: December 15, 2014
    Publication date: October 20, 2016
    Applicant: Novo Nordisk Health Care AG
    Inventors: Charlotte Schou Hunneche, Thomas Budde Hansen, Ernst Broberg Hansen
  • Cyanoguanidines as cell proliferation inhibitors
    Patent number: 6646129
    Abstract: The present invention relates to hitherto unknown compounds of formula (I) or their tautomeric forms, the attachment to the pyridine ring being in the 3- or 4-position, in which formula R stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, halogen, trifluoromethyl, carboxy, C1-C4 alkyl, alkoxy or alkoxycarbonyl, nitro, amino or cyano and Q stands for C5-C14 divalent hydrocarbon radical which can be straight, branched, cyclic, saturated or unsaturated and X stands for carboxy, C1-C4 alkoxycarbonyl, di(C1-C4 alkoxy)-phosphinoyloxy, amino, C1-C4 alkoxycarbonylamino or tetrahydropyranyloxy; and pharmaceutically acceptable, non-toxic salts and N-oxides thereof. The present compounds are of value in the human and veterinary practice.
    Type: Grant
    Filed: February 4, 2002
    Date of Patent: November 11, 2003
    Assignee: Leo Pharmaceutical Products Ltd. A/S
    Inventors: Charlotte Schou Hunneche, Erik Rytter Ottosen
  • Cyanoguanidines as cell proliferation inhibitors
    Publication number: 20020107400
    Abstract: The present invention relates to hitherto unknown compounds of formula (I) or their tautomeric forms, 1
    Type: Application
    Filed: February 4, 2002
    Publication date: August 8, 2002
    Applicant: Leo Pharmaceutical Products Ltd. A/S
    Inventors: Charlotte Schou Hunneche, Erik Rytter Ottosen
  • Cyanoguanidines as cell proliferation inhibitors
    Patent number: 6346520
    Abstract: The present invention relates to hitherto unknown compounds of formula (I) or their tautomeric forms, the attachment to the pyridine ring being in the 3- or 4-position, in which formula R stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, halogen, trifluoromethyl, carboxy, C1-C4 alkyl, alkoxy or alkoxycarbonyl, nitro, amino or cyano and Q stands for C5-C14 divalent hydrocarbon radical which can be straight, branched, cyclic, saturated or unsaturated and X stands for carboxy, C1-C4 alkoxycarbonyl, di(C1-C4 alkoxy)phosphinoyloxy, amino, C1-C4 alkoxycarbonylamino or tetrahydropyranyloxy; and pharmaceutically acceptable, non-toxic salts and N-oxides thereof. The present compounds are of value in the human and veterinary practice.
    Type: Grant
    Filed: November 26, 1999
    Date of Patent: February 12, 2002
    Assignee: Leo Pharmaceutical Products, Ltd. A/S
    Inventors: Charlotte Schou Hunneche, Erik Rytter Ottosen
  • Cyanoguanidines as cell proliferation inhibitors
    Patent number: 6346541
    Abstract: The present invention relates to hitherto unknown compounds of formula (I) or their tautomeric forms, the attachment to the pyridine ring being in the 3- or 4-position, in which formula R1 stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, halogen, trifluoromethyl, carboxy, C1-C4 alkyl, alkoxy or alkoxycarbonyl, nitro, amino or cyano and Q stands for C4-C20 divalent hydrocarbon radical which can be straight, branched, cyclic, saturated or unsaturated and X stands for carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothiocarbonyloxy, oxycarbonylamino or oxythiocarbonylamino and Y stands for benzylene or phenylene and R2 stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, C1-C4 alkyl, hydroxyalkyl or alkoxy, hydroxy, halogen, trifluoromethyl, cyano, carboxamido, sulfamoyl, nitro, amino, ca
    Type: Grant
    Filed: November 26, 1999
    Date of Patent: February 12, 2002
    Assignee: Leo Pharmaceutical Products Ltd. A/S
    Inventor: Charlotte Schou Hunneche
  • Cyanoguanidines as cell proliferation inhibitors
    Patent number: 6300345
    Abstract: Compounds of the following formula are used for inhibiting cell proliferation: wherein R, Q1, Q2, X are as defined in the specification.
    Type: Grant
    Filed: November 26, 1999
    Date of Patent: October 9, 2001
    Assignee: Leo Pharmacuetical Products Ltd. A/S (Løvens kemiske Fabrik Produktionsaktieselskab)
    Inventors: Charlotte Schou Hunneche, Hans Jørgen Petersen